Status:
UNKNOWN
Prediction of Response to Treatment of Patients With Chronic HCV Infection by Genetic Profile
Lead Sponsor:
Hadassah Medical Organization
Conditions:
Hepatitis C Virus Chronic Infection
Eligibility:
All Genders
18-80 years
Brief Summary
We hypothesized that pretreatment nonresponder and responder liver tissue would show consistent differences in gene expression levels and that these differences could be used to predict treatment outc...
Detailed Description
Hepatitis C virus is a leading cause of chronic liver disease, with over 170 million people infected worldwide. It is also the leading indication for liver transplantation. Complications from chronic ...
Eligibility Criteria
Inclusion
- PATIENTS COMPLETING TREATMENT WITH PEGINTERFERON AND RIBAVIRIN FOR CHRONIC HCV INFECTION AND UNDERWENT LIVER BIOPSY PRIOR THERAPY ONSET
Exclusion
- TREATMENT NOT COMPLETED
Key Trial Info
Start Date :
March 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2006
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00272389
Start Date
March 1 2006
End Date
May 1 2006
Last Update
January 6 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah Medical Organization
Jerusalem, Israel